Vital Energy, Inc. (VTLE)
NYSE: VTLE · Real-Time Price · USD
16.91
-1.78 (-9.52%)
At close: Aug 1, 2025, 4:00 PM
16.93
+0.02 (0.12%)
After-hours: Aug 1, 2025, 7:56 PM EDT
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Verve Therapeutics stock have a consensus rating of "Hold" and an average price target of $26.75, which forecasts a 58.19% increase in the stock price over the next year. The lowest target is $17 and the highest is $47.
Price Target: $26.75 (+58.19%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Verve Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 0 | 1 | 1 | 1 | 0 | 0 |
| Hold | 5 | 5 | 6 | 7 | 7 | 7 |
| Sell | 2 | 2 | 2 | 2 | 3 | 3 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $15 → $17 | Hold | Maintains | $15 → $17 | +0.53% | Jul 17, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $21 → $22 | Hold | Maintains | $21 → $22 | +30.10% | Jul 15, 2025 |
| Raymond James | Raymond James | Buy → Sell Downgrades n/a | Buy → Sell | Downgrades | n/a | n/a | Jun 24, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $24 → $21 | Hold | Maintains | $24 → $21 | +24.19% | Jun 16, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $16 → $15 | Hold | Maintains | $16 → $15 | -11.30% | May 15, 2025 |
Financial Forecast
Revenue This Year
2.01B
from 1.95B
Increased by 3.06%
Revenue Next Year
1.90B
from 2.01B
Decreased by -5.42%
EPS This Year
7.57
from -4.74
EPS Next Year
4.76
from 7.57
Decreased by -37.10%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.2B | 2.2B | 2.2B |
| Avg | 2.0B | 1.9B | 2.0B |
| Low | 1.8B | 1.6B | 1.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.2% | 11.6% | 13.2% |
| Avg | 3.1% | -5.4% | 2.9% |
| Low | -8.3% | -18.9% | -9.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 9.87 | 10.31 | 9.94 |
| Avg | 7.57 | 4.76 | 5.36 |
| Low | 4.79 | 1.27 | 2.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 36.1% | 108.7% |
| Avg | - | -37.1% | 12.5% |
| Low | - | -83.2% | -43.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.